Close Menu

codevelopment agreement

The companies will develop an in silico predictive modeling system for use in drug development ADMET applications.

The companies will use Luminex's xMAP technology to develop an automated biothreat detection tool for a US biosecurity network.

The companies will co-develop and co-market ion channel genes for mammalian cell line research.

The companies will use Cellzome's Episphere chemical proteomics technology to identify candidates for anti-inflammatory drugs. If certain milestones are met, Cellzome could potentially receive €475 million.

Following a scientific data review, ExonHit Therapeutics and BioMerieux have decided to discontinue their colon cancer collaboration.

The company will work with Semmelweis University to develop micromethods for handling small biosamples for microarray analysis.


The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.